New Pancreas Biomarkers Detected Early in Type 1 Diabetes Development

Researchers followed 301 children at risk for Type 1 diabetes from birth as part of the Environmental Determinants of Islet Autoimmunity (ENDIA) cohort. Over time, they collected 1,679 stool samples and 1,014 blood serum samples to measure two pancreatic enzymes: fecal elastase-1 (FE-1) and immunoreactive trypsin (IRT).

These enzymes are produced by the exocrine pancreas—the part of the pancreas that makes digestive juices. The researchers compared enzyme levels in children who developed islet autoimmunity or Type 1 diabetes with levels in children who remained healthy.

The study identified two distinct patterns. Children who later developed multiple islet autoantibodies or Type 1 diabetes had noticeably lower FE-1 levels starting at birth and continuing through the first 6 months of life. These differences were detectable even before any autoimmune markers appeared.

A second pattern emerged with immunoreactive trypsin: children who eventually developed Type 1 diabetes had lower IRT levels 12 and 18 months before their diagnosis. This suggests a measurable decline in pancreatic enzyme production occurred well before clinical disease onset.

Type 1 diabetes has long been understood as primarily an autoimmune disease affecting the insulin-producing beta cells in the pancreas. This study adds evidence that the exocrine pancreas—the digestive enzyme-producing part—may also play an important role in disease development.

The early detection of enzyme changes, particularly visible from birth onward, suggests that pancreatic exocrine dysfunction may be part of the disease process earlier than previously recognized. Understanding these patterns could help researchers piece together how Type 1 diabetes develops over time.

These findings are from observational research designed to identify associations, not to predict or diagnose Type 1 diabetes in individual children. Much more work is needed to understand whether these biomarker changes cause disease progression, are a consequence of early immune changes, or occur independently.

If future research confirms the value of these biomarkers, they could eventually contribute to a more complete picture of how and why Type 1 diabetes develops, potentially opening new avenues for understanding disease prevention and progression.

Source: Diabetes care. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.